News

The ISN has expanded its “Cardio-Kidney-Metabolic (CKM) Initiative” with the launch of a new interactive CKM roadmap designed to help clinicians manage patients with cardio-kidney-metabolic conditions and complications.

Access the roadmap here

Kidney, cardiovascular, and metabolic diseases are closely linked, contributing significantly to morbidity and mortality worldwide. Launched in 2022, the CKM initiative brings nephrologists and cardiologists together to address gaps in therapy, management, and implementation barriers.

 Why explore the roadmap? 

The interactive roadmap offers multiple resources, including:

• A dynamic and user-friendly tool to interpret eGFR and albuminuria data, aiding in patient management decisions
• Practical guidance for optimizing care in complex co-morbidities

Explore the CKM toolkit library 

The ISN’s CKM Initiative also includes a series of toolkits to support clinicians:

• The “Optimization of RAASi Therapy Toolkit” is available in multiple languages, featuring infographics and references for healthcare professionals managing cardio-kidney complications

Upcoming CKM-related additions

• The “Optimization of SGLT2i Therapy Toolkit” will launch by the end of 2024, with translations available in early 2025
• In 2025, a new toolkit on combination therapies will provide additional valuable resources for integrated care

Discover the interactive roadmap and stay tuned for upcoming toolkits to advance care for people living with kidney diseases worldwide. 

The cardio-kidney-metabolic initiative is supported by unrestricted educational grants from AstraZeneca, CSL Vifor, Novo Nordisk, and Boehringer Ingelheim and its alliance partner, Lilly.